Rucaparib (Rubraca) for platinum-sensitive, high-grade serous or endometrioid epithelial ovarian cancer, primary peritoneal or fallopian tube cancer

Ovarian cancer is the most common type of cancer in women. It mainly affects old age women but can also affect young women. Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer. Inherited gene mutations (faults) increase the risk for ovarian cancer. Primary peritoneal cancer (PPC) is a rare cancer of the peritoneum (a layer of thin tissue that lines the inside of the tummy and covers all of the organs within it). PPC mainly affects women and it is very similar to EOC. Fallopian tube cancer is a rare cancer of the fallopian tube (tubes that connect the ovaries to the womb).
Rucaparib is a medicinal product under development for the treatment of patients with platinum-sensitive, high-grade serous or endometrioid EOC, primary peritoneal or fallopian tube cancer. Rucaparib has anti-tumour activity by blocking the effect of certain enzymes leading to the death of tumour cells. Rucaparib is given by mouth as tablets. If licensed, rucaparib will offer an additional treatment option for patients with platinum-sensitive relapsed, high-grade serous or endometrioid EOC, primary peritoneal or fallopian tube cancer.